Untung Rugi Penggunaan Furosemide pada Gagal Ginjal Tahap Lanjut

Oleh :

dr.Eduward Thendiono, SpPD,Finasim,IDF-Fellow

Penggunaan furosemide pada gagal ginjal tahap lanjut kerap menjadi dilema, terutama terkait efikasi, keamanan, dan manfaat jangka panjangnya. Di satu sisi, furosemide digunakan untuk mengendalikan kelebihan cairan, mengurangi edema, dan memperbaiki gejala kongestif. Di sisi lain, penggunaannya pada pasien dengan fungsi ginjal yang sangat terbatas dapat menimbulkan risiko seperti ketidakseimbangan elektrolit, hipotensi, maupun nefrotoksisitas.

Peran Furosemide dalam Penanganan Gagal Ginjal Tahap Lanjut

Seiring penurunan fungsi ginjal pada pasien penyakit ginjal kronis (CKD), sejumlah zat terlarut yang normalnya dikeluarkan dari ginjal yang sehat akan tertahan di tubuh. Akumulasi zat terlarut tersebut dapat mengganggu satu atau lebih fungsi biologis normal. Hal ini disebut dengan uremic toxin.[1,2]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Vanholder R, Pletinck A, Schepers E, Glorieux G. Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update. Toxins. 2018;10:33. https://doi.org/10. 3390 /toxins 10010033
2. Rosner MH, Reis T, Husain-Syed F, et al. Classiﬁcation of uremic toxins and their role in kidney failure. Clin J Am Soc Nephrol.2021;16:1918–1928. https://doi.org/10.2215/CJN.02660221
3. El Chamieh C, Liabeuf S, Massy Z. Uremic toxins and cardiovascular risk in chronic kidney disease: what have we learned recently beyond the past ﬁndings? Toxins. 2022;14:280. https:// doi.org/ 10.3390 /toxins14040280
4. Nigam SK, Bush KT. Uremic syndrome of chronic kidney disease: altered remote sensing and signaling. Nat Rev Nephrol.2019;15:301–316. https://doi.org/10.1038/s41581-019-0111-1
5. Daneshamouz S, Eduok U, Abdelrasoul A, Shoker A. Protein-bound uremic toxins (PBUTs) in chronic kidney disease (CKD) patients: production pathway, challenges and recent advances in renal PBUTs clearance. NanoImpact. 2021;21:100299. https:// doi.org/ 10.1016/ j.impact. 2021.100299
6. Oosting IJ, Colombijn JMT, Kaasenbrood L, et al. Polypharmacy in patients with CKD: a systematic review and meta-analysis. Kidney360. 2024;5:841–850. https://doi.org/ 10.34067/ KID.0000000000000447
7. Nigam SK, Bush KT, Martovetsky G, et al. The organic anion transporter (OAT) family: a systems biology perspective.Physiol Rev. 2015;95:83–123. https://doi.org/10.1152/physrev.00025.2013
8. Huo X, Liu K. Renal organic anion transporters in drug–drug interactions and diseases. Eur J Pharm Sci. 2018;112:8–19.https://doi.org/10.1016/j.ejps.2017.11.001
9. Mihaila SM, Faria J, Stefens MFJ, et al. Drugs commonly applied to kidney patients may compromise renal tubularuremic toxins excretion. Toxins (Basel). 2020;12:391. https://doi.org /10.3390/toxins12060391
10. André C, Mernissi T, Choukroun G, et al. The prescription of drugs that inhibit organic anion Transporters 1 or 3 is associated with the plasma accumulation of uremic toxins in kidney transplant recipients. Toxins (Basel). 2021;14:15.https://doi.org/10.3390/toxins14010015
11. Vallon V, Rieg T, Ahn SY, Wu W, Eraly SA, Nigam SK.Overlapping in vitro and in vivo speciﬁcities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Ren Physiol. 2008;294:F867–F873.https://doi.org/10.1152/ajprenal.00528.2007
12. Tsuruya Y, Kato K, Sano Y, et al. Investigation of endogenous compounds applicable to drug–drug interaction studies involving the renal organic anion transporters, OAT1 and OAT3, in humans. Drug Metab Dispos. 2016;44:1925–1933. https://doi.org/10.1124/dmd.116.071472
13. Ingwiller M, Bozman DF, Florens N, et al. Diuretics and mortality reduction in incident dialysis patients: a two-year observational study. Sci Rep. 2024;14:27447. https://doi.org /10.1038/s41598-024-65643-8
14. Lemes, H. P. et al. Use of small doses of furosemide in chronic kidney disease patients with residual renal function undergoing hemodialysis. Clin. Exp. Nephrol.2011. 15(4), 554–9.
15. van Olden, R. W., van Meyel, J. J. & Gerlag, P. G. Acute and long-term efects of therapy with high-dose furosemide in chronic hemodialysis patients. Am. J. Nephrol. 12(5), 351–356 (1992).
16. Medcalf, J. F., Harris, K. P. & Walls, J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 2001;59(3): 1128–1133.
17. Bragg-Gresham, J. L. et al. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Out-comes and Practice Pattern Study (DOPPS). Am. J. Kidney Dis.2007; 49(3): 426–431.
18. Sibbel, S. et al. Association of continuation of loop diuretics at hemodialysis initiation with clinical outcomes. Clin. J. Am. Soc. Nephrol.2019;14(1): 95–102.
19. Costes-Albrespic M, Alencar de Pinho N, Larabi IA, et al.Furosemide and serum protein-bound uremic toxin concentrations in patients with CKD. Kidney Int Rep. 2025;10:2165–2177. https://doi.org/10.1016/j.ekir.2025.04.040
20. Bertocchio JP. Furosemide, an old friend of nephrologists for the treatment CKD: time to rethink the relationship? Kidney Int Rep. 2025;10:2094–2096. https://doi.org/ 10. 1016/ j.ekir. 2025. 05.021